Tudor Investment Corp Et Al acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) during the 3rd quarter, Holdings Channel reports. The fund acquired 24,332 shares of the company’s stock, valued at approximately $205,000.
Several other institutional investors and hedge funds have also made changes to their positions in PTGX. State Street Corp boosted its position in shares of Protagonist Therapeutics by 108.1% in the 2nd quarter. State Street Corp now owns 6,776,269 shares of the company’s stock worth $53,600,000 after buying an additional 3,519,461 shares in the last quarter. Bain Capital Life Sciences Investors LLC purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at about $17,881,000. Renaissance Technologies LLC lifted its holdings in Protagonist Therapeutics by 1,558.5% in the 2nd quarter. Renaissance Technologies LLC now owns 322,867 shares of the company’s stock valued at $2,554,000 after purchasing an additional 303,400 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Protagonist Therapeutics by 82.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 631,916 shares of the company’s stock valued at $4,999,000 after purchasing an additional 285,557 shares in the last quarter. Finally, Walleye Capital LLC lifted its holdings in Protagonist Therapeutics by 670.8% in the 2nd quarter. Walleye Capital LLC now owns 257,357 shares of the company’s stock valued at $2,036,000 after purchasing an additional 223,967 shares in the last quarter. 91.51% of the stock is currently owned by hedge funds and other institutional investors.
Protagonist Therapeutics Price Performance
NASDAQ PTGX opened at $25.00 on Friday. Protagonist Therapeutics, Inc. has a 12 month low of $6.91 and a 12 month high of $27.41. The company has a 50-day moving average of $14.83 and a 200-day moving average of $10.72. The company has a market cap of $1.23 billion, a P/E ratio of -9.33 and a beta of 2.01.
Analyst Upgrades and Downgrades
About Protagonist Therapeutics
Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
- Get a free copy of the StockNews.com research report on Protagonist Therapeutics (PTGX)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.